Eli Lilly snaps up leading Alzheimer's diagnostic

Date November 08, 2010

Despite losing its lead Alzheimer’s disease candidate three months ago, Eli Lilly has signalled its ongoing interest in the field with the $300m acquisition of diagnostics player Avid Radiopharmaceuticals.

Avid has already filed florbetapir, a molecular imaging agent that can detect amyloid plaque in the brain, with the FDA. If it wins approval, florbetapir would be the first proven diagnostic for Alzheimer’s in living patients. The move also underscores Lilly’s intentions in diagnostics; earlier this year a new division was formed to specifically work in this area and this acquisition could rapidly accelerate its presence.

Strong correlation

Lilly could end up paying an additional $500m for Avid, should florbetapir reach various regulatory and commercial milestones.

The company believes it has established a strong correlation between florbetapir-PET scan results and the levels of beta-amyloid pathology in brains at autopsy. Although doctors can be fairly confident in Alzheimer’s diagnosis clinically, currently the only way to confirm the presence of the disease is to look for the classic plaques and tangles in the brain after death.

Having a proven diagnostic test available for living patients would be a big step forward, particularly if it means the disease can be diagnosed earlier. Researchers believe the plaque and tangles can be present for a decade in some patients, before symptoms manifest.

Florbetapir, also called AV-45, is injected into patients and then crosses the blood brain barrier, binding to beta-amyloid plaques and essentially dying them. This can be picked up on a PET scan.

Theoretically, the agent could also be used to monitor disease progression and possibly even drug efficacy. With numerous Alzheimer's agents in the pipeline targeting beta-amyloid, florbetapir holds the potential to become a useful tool in the diagnosis and treatment of Alzheimer’s.

Dominant theory

Following the failure of semagacestat, Lilly has two further Alzheimer’s candidates in active development. The most advanced, solanezumab, is an antibody designed to break up the beta amyloid clumps. Two phase III trials started in May 2009 and will report late next year or possibly 2012.

Still in phase I the company has a BACE or ß-Secretase inhibitor called LY2811376. The ß-Secretase enzyme is thought to be involved in the formation of amyloid plaques, so its inhibition could theoretically help slow or stop the disease.

The beta-amyloid theory - that these clumps kill brain cells and cause Alzheimer’s – informs the majority of Alzheimer's therapies in the pipeline (Therapeutic focus - What are plan B options if A-beta Alzheimer's hypothesis is void?, August 19, 2010).

However, this theory is far from proven. The failure of semagacestat, a gamma secretase inhibitor, certainly prompted concerns about this approach (Will gamma secretase Alzheimer's class survive the fall of semagacestat?, August 18, 2010).

Stands or falls

Whether this theory stands or falls should not impact florbetapir as a diagnostic tool, as detecting the presence of beta-amyloid will remain a marker of Alzheimer's. And of course Avid, and now Lilly, is not the only company with a late-stage Alzheimer's diagnostic.

Avid is the source of an agent Bayer has in phase III studies, called florbetaben, that also uses a tracer that binds to beta-amyloid, detected with PET scans. Results should be available next year. GE Healthcare has another in late stage studies, flutemetamol, which is also close to generating phase III data, according to www.clinicaltrials.gov.

However what will help these diagnostics is growing evidence supporting the beta-amyloid theory. This would mean they could also be used to help predict drug efficacy.

This evidence could be some time coming, but might well come from Lilly with solanezumab, possibly the latest-stage product targeting amyloid beta. Pfizer's bapineuzumab is the other phase III agent in this area, with data due around the same time.

With so much riding on this theory, positive results are wished for in all quarters.

This content is written, edited and published by EP Vantage and is distributed by Evaluate Ltd. All queries regarding the content should be directed to: news@epvantage.com

EP Vantage is a unique, forward-looking, news analysis service tailored to the needs of pharma and finance professionals. EP Vantage focuses on the events that will define the future of companies, products and therapy areas, with detailed financial analysis of events in real-time, including regulatory decisions, product approvals, licensing deals, patent decisions, M&A.

Drawing on Evaluate, an industry-leading database of actual and forecast product sales and financials, EP Vantage gives readers the insight to make value-enhancing decisions.

EP Vantage SM ©2018 EP Vantage Ltd